Swiss National Bank Decreases Stake in Xencor, Inc. $XNCR

Swiss National Bank decreased its holdings in shares of Xencor, Inc. (NASDAQ:XNCR) by 6.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 115,300 shares of the biopharmaceutical company’s stock after selling 8,300 shares during the quarter. Swiss National Bank owned approximately 0.16% of Xencor worth $1,227,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in XNCR. RTW Investments LP lifted its stake in Xencor by 317.9% during the fourth quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company’s stock worth $55,218,000 after purchasing an additional 1,827,883 shares during the last quarter. BVF Inc. IL lifted its stake in Xencor by 169.3% during the fourth quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company’s stock worth $52,596,000 after purchasing an additional 1,438,760 shares during the last quarter. Primecap Management Co. CA lifted its stake in Xencor by 8.6% during the first quarter. Primecap Management Co. CA now owns 9,761,012 shares of the biopharmaceutical company’s stock worth $103,857,000 after purchasing an additional 776,580 shares during the last quarter. Nuveen Asset Management LLC lifted its stake in Xencor by 452.4% during the fourth quarter. Nuveen Asset Management LLC now owns 837,082 shares of the biopharmaceutical company’s stock worth $19,236,000 after purchasing an additional 685,557 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its stake in Xencor by 150.4% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 519,976 shares of the biopharmaceutical company’s stock worth $11,949,000 after purchasing an additional 312,354 shares during the last quarter.

Xencor Price Performance

Xencor stock opened at $8.01 on Tuesday. Xencor, Inc. has a 1-year low of $6.92 and a 1-year high of $27.24. The company has a market cap of $571.27 million, a PE ratio of -3.34 and a beta of 0.89. The stock’s 50 day moving average price is $8.32 and its 200 day moving average price is $10.06.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.37. The firm had revenue of $43.61 million for the quarter, compared to the consensus estimate of $22.59 million. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%.The company’s revenue for the quarter was up 82.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.07) earnings per share. On average, equities research analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on XNCR. Wells Fargo & Company decreased their target price on Xencor from $33.00 to $27.00 and set an “overweight” rating for the company in a research note on Thursday, August 7th. Royal Bank Of Canada decreased their target price on Xencor from $32.00 to $15.00 and set an “outperform” rating for the company in a research note on Thursday, August 21st. Barclays cut their price target on Xencor from $22.00 to $6.00 and set an “underweight” rating on the stock in a research report on Thursday, May 8th. Finally, Wedbush cut their price target on Xencor from $31.00 to $26.00 and set an “outperform” rating on the stock in a research report on Thursday, August 7th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $23.71.

Insiders Place Their Bets

In other Xencor news, Director Kurt A. Gustafson sold 2,993 shares of the business’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $9.22, for a total transaction of $27,595.46. Following the sale, the director directly owned 20,183 shares in the company, valued at approximately $186,087.26. The trade was a 12.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ellen Feigal sold 2,993 shares of the business’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the sale, the director owned 19,183 shares in the company, valued at approximately $176,867.26. The trade was a 13.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 11,194 shares of company stock worth $103,209. 5.23% of the stock is owned by corporate insiders.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.